No Data
Express News | Cassava Sciences' Phase 3 Trial Expected To Conclude By December 2024 With 804 Patients; Second Trial With 1,125 Patients To End By June 2025; Successful Results Could Be Revolutionary
Express News | Cassava Sciences Shares Are Trading Higher After the Company Announced Its First Phase 3 Trial Is Expected to Conclude by December and Its Second Phase 3 Trial Is Expected to Conclude by June 2025
Cassava Sciences Chairman Shares Insights in Open Letter
Express News | Cassava Sciences Shares up 3.2% Premarket; Data From Late-Stage Trial of Co's Alzheimer's Drug Is Expected in December
Express News | Cassava Sciences Executive Chairman Rick Barry Issues An Open Letter To "Shareholders, Employees, Principal Investigators, Patients And Their Loved Ones" On July 21, 2024
Express News | Cassava Sciences : Board Is 100% Committed to Completing Phase 3 Program, Releasing Results on Time